Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT04644107
NCT04644107No Longer AvailableNot Applicable

Expanded Access for Marizomib

Celgene1 site in 1 countryStarted: November 25, 2020Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
No Longer Available
Sponsor
Celgene
Locations
1
Study OverviewEligibility CriteriaInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This is an expanded access program (EAP) for eligible participants designed to provide access to Marizomib.

Study Design

Study Type
Expanded Access

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Investigators

Sponsor
Celgene
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

No Longer Available
Not Applicable
Expanded Access to EpcoritamabLymphoma
NCT05692050AbbVie
No Longer Available
Not Applicable
US Expanded Access Program for Magrolimab in Patients With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed/Refractory Acute Myeloid Leukemia
NCT05627466Gilead Sciences
No Longer Available
Not Applicable
Expanded Access to ElezanumabAcute Spinal Cord Injury (SCI)Acute Spinal Cord Injury (SCI)
NCT04278235AbbVie
No Longer Available
Not Applicable
Expanded Access to Bimatoprost (Durysta)Open-angle Glaucoma
NCT05338606AbbVie
Approved For Marketing
Not Applicable
An Expanded Access Program of Emicizumab in Participants With Hemophilia A With InhibitorsHemophilia A
NCT03154437Genentech, Inc.